TOOKAD SOLUBLE 200 MG

Страна: Израиль

Язык: английский

Источник: Ministry of Health

Активный ингредиент:

PADELIPORFIN DIPOTASSIUM

Доступна с:

STEBA LABORATORIES LTD., ISRAEL

Фармацевтическая форма:

POWDER FOR SOLUTION FOR INFUSION

состав:

PADELIPORFIN DIPOTASSIUM 200 MG

Администрация маршрут:

I.V

Тип рецепта:

Required

Производитель:

STEBA LABORATORIES LTD., ISRAEL

Терапевтические показания :

TOOKAD soluble is indicated for adult patients with unilateral low risk localised prostate cancer and with a life expectancy ≥ 10 years and:- - Clinical stage up to T2a, - Gleason Score ≤ 6, based on high-resolution biopsy strategies, - PSA ≤ 10 ng/mL, - Up to 3 independent positive cores- mpMRI by 3T without endo-rectal coil showing normal MRI or unilateral tumor without evidence of capsular or seminal vesicle involvement or metastatic tumor to lymph nodes.TOOKAD is administered as part of focal Vascular-Targeted Photodynamic therapy (VTP).

Дата Авторизация:

2022-06-30

тонкая брошюра

TOOKAD
®
Soluble – Patient Information Guide - v1.1 IL 19-10-2017
1
TOOKAD
®
SOLUBLE
(PADELIPORFIN DIPOTASSIUM)
PATIENT INFORMATION BROCHURE
TOOKAD
®
Soluble is used to treat
low-risk localized prostate cancer
Date of approval: December 2017
TOOKAD
®
Soluble – Patient Information Guide - v1.1 IL 19-10-2017
2
1. WHAT ARE THE AIMS OF THIS GUIDE?
You have been given this guide by your doctor because you have a
low-risk localised prostate
cancer. A Vascular-Targeted Photodynamic therapy (VTP) with TOOKAD
®
Soluble is a treatment
option for your cancer.
This guide does not determine what the best treatment for you is - you
will discuss this with your
doctor. It presents the possible benefits, risks and uncertainties
associated with TOOKAD
®
Soluble-
VTP in order to help you make an informed decision.
2. HOW IS LOW-RISK PROSTATE CANCER TREATED?
The long term survival rate for patients with low-risk prostate cancer
is, on average, over 95% after
10 years. Treatment options include active surveillance (which
involves regular review, intermittent
prostate biopsy and treatment if the disease gets worse) and active
therapies, including radical
prostatectomy (surgical removal of the prostate), radiotherapy,
brachytherapy (insertion of
radioactive implants into the prostate), high-intensity focused
ultrasound (HIFU), VTP with
TOOKAD
®
Soluble or destruction of the tissue by using extreme cold
(cryoablation) . Your doctor will
explain these treatment options to you.
3. WHAT IS TOOKAD
®
SOLUBLE?
TOOKAD
®
Soluble is a medicine that contains a substance called padeliporfin
dipotassium that
causes the body’s tissues and organs to become sensitive to light.
The medicine is injected into the
bloodstream and then activated by laser light, shone along optic
fibres into the prostate. The
treatment is carried out under general anaesthetic.
4. WHAT ARE THE POTENTIAL BENEFITS OF TOOKAD
® SOLUBLE?
The benefits of TOOKAD
®
Soluble are its ability to improve the probability of a negative
biopsy after
24 months as well as del